Curie Brief
Turn on cookies to sign in
Signing in saves your progress to your Curie account. We can only do that with cookies on — turn them on to continue.
News
Real-world data back up clinical trial results for liso-cel in relapsed/refractory mantle cell lymphoma. Across two analyses totaling 155 patients, overall response rates hit 85–89% and complete response rates reached 79–82%, mirroring the pivotal TRANSCEND MCL trial. Safety was manageable, with most toxicities being low-grade — offering reassurance for broader clinical use.
Two real-world analyses presented at the 2026 Society of Hematologic Oncology (SOHO) Annual Meeting confirm that lisocabtagene maraleucel (liso-cel), a CD19-directed CAR T-cell therapy, performs in everyday clinical practice just as well as it did in the clinical trial that earned its FDA approval in May 2024. The larger analysis — the first real-world dataset for liso-cel in relapsed/refractory mantle cell lymphoma (MCL) — included 121 patients from the CIBMTR registry, while a second independent study covered 34 patients across 10 US institutions.
Patients in both studies were older and had more comorbidities than typical trial participants, yet response rates remained high and toxicity profiles stayed manageable. Notably, 53% of patients in the larger cohort would have been ineligible for the original TRANSCEND MCL trial — yet their outcomes were nearly identical to the broader group.
By the Numbers:
Why it matters: These are the first real-world data for liso-cel in relapsed/refractory MCL — a disease with few effective options after BTK inhibitor failure. The consistency between trial and real-world results builds confidence for clinicians treating older, sicker patients, while late infection rates (up to 38%) underscore the need for long-term post-infusion surveillance.
